Combination therapy for resectable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have non-small cell lung cancer that can be removed by surgery.
- You must be in generally good health, with an ECOG performance status of 0 or 1 (able to carry out daily activities).
- Your organs must be working well enough, as determined by routine blood and lab tests.
- If you can become pregnant, you must have a negative pregnancy test and agree to use effective birth control.
- You must not have active autoimmune disease, other cancers in the past 5 years, or serious lung or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This Phase 3 trial studies whether an immunotherapy drug (SHR-1316) added to standard chemotherapy helps people live longer or delay cancer returning after surgery. It focuses on people with resectable non-small cell lung cancer (NSCLC) that has not been treated before.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests two drugs, SHR-A1811 and AK112, for people with advanced non-small cell lung cancer that has HER2 changes. It may help if you have not improved on standard treatment or if you have not yet had treatment.
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
This trial tests a new combination of drugs (an immunotherapy and a possible new treatment) plus chemotherapy for people with advanced lung cancer. The goal is to see if this combination can shrink tumors or stop them from growing.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.